Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 4Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Recurrence 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Tracheal Diseases 1Stomach Neoplasms 1Smoking Cessation 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Peritoneal Neoplasms 1Pain, Postoperative 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasms, Plasma Cell 1Mucopolysaccharidosis I 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Lymphedema 1Lung Neoplasms 1Locally Advanced Rectal Cancer 1Liposarcoma 1

Interventions

Temozolomide 393Radiotherapy 196Bevacizumab 156Radiation 77Magnetic Resonance Spectroscopy 68Lomustine 47Surgical Procedures, Operative 42Carmustine 41pembrolizumab 39Irinotecan 38Nivolumab 32Specimen Handling 27Carboplatin 27Radiosurgery 24Erlotinib Hydrochloride 24Chemotherapy, Adjuvant 23Radiotherapy, Intensity-Modulated 22Drug Therapy 21Cyclophosphamide 20Aminolevulinic Acid 20O(6)-benzylguanine 17sargramostim 16Radiotherapy, Conformal 15temsirolimus 14Granulocyte-Macrophage Colony-Stimulating Factor 14Everolimus 14Vorinostat 13Sorafenib 13poly ICLC 12atezolizumab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Glioblastoma × Combined Modality Therapy × Clear all
NCT00805961 2021-12-08

RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM

SCRI Development Innovations, LLC

Phase 2 Completed
68 enrolled 8 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡